MBX Biosciences to Participate in Citizens and RBC May Investor Conferences
MBX Biosciences (Nasdaq: MBX), a clinical-stage biopharmaceutical company specializing in precision peptide therapies for endocrine and metabolic disorders, has announced its participation in two major investor conferences in May 2025.
The company's President and CEO, Kent Hawryluk, will present at the Citizens Life Sciences Conference on May 7, 2025 (3:00-3:25 p.m. ET) and the RBC 2025 Global Healthcare Conference on May 21, 2025 (3:35-4:00 p.m. ET). Both events will be held in New York and will feature fireside chats along with one-on-one meetings.
Investors can access live webcasts of both presentations through the company's website at investors.mbxbio.com/news-events/events. Replay recordings will be available approximately two hours after each event and remain accessible for 90 days.
MBX Biosciences (Nasdaq: MBX), un'azienda biofarmaceutica in fase clinica specializzata in terapie peptidiche di precisione per disturbi endocrini e metabolici, ha annunciato la sua partecipazione a due importanti conferenze per investitori nel maggio 2025.
Il Presidente e CEO dell'azienda, Kent Hawryluk, interverrà alla Citizens Life Sciences Conference il 7 maggio 2025 (15:00-15:25 ET) e alla RBC 2025 Global Healthcare Conference il 21 maggio 2025 (15:35-16:00 ET). Entrambi gli eventi si terranno a New York e includeranno conversazioni informali e incontri individuali.
Gli investitori potranno seguire le dirette streaming di entrambe le presentazioni tramite il sito web dell'azienda all'indirizzo investors.mbxbio.com/news-events/events. Le registrazioni saranno disponibili circa due ore dopo ogni evento e resteranno accessibili per 90 giorni.
MBX Biosciences (Nasdaq: MBX), una empresa biofarmacéutica en etapa clínica especializada en terapias peptídicas de precisión para trastornos endocrinos y metabólicos, ha anunciado su participación en dos importantes conferencias para inversores en mayo de 2025.
El presidente y CEO de la compañía, Kent Hawryluk, presentará en la Citizens Life Sciences Conference el 7 de mayo de 2025 (3:00-3:25 p.m. ET) y en la RBC 2025 Global Healthcare Conference el 21 de mayo de 2025 (3:35-4:00 p.m. ET). Ambos eventos se realizarán en Nueva York e incluirán charlas informales y reuniones uno a uno.
Los inversores podrán acceder a las transmisiones en vivo de ambas presentaciones a través del sitio web de la compañía en investors.mbxbio.com/news-events/events. Las grabaciones estarán disponibles aproximadamente dos horas después de cada evento y permanecerán accesibles durante 90 días.
MBX Biosciences (나스닥: MBX)는 내분비 및 대사 질환을 위한 정밀 펩타이드 치료제를 전문으로 하는 임상 단계 바이오제약 회사로, 2025년 5월 두 개의 주요 투자자 컨퍼런스에 참여할 예정임을 발표했습니다.
회사의 사장 겸 CEO인 켄트 하우릴룩(Kent Hawryluk)은 2025년 5월 7일 (동부시간 오후 3:00-3:25) 시티즌스 생명과학 컨퍼런스와 2025년 5월 21일 (동부시간 오후 3:35-4:00) RBC 2025 글로벌 헬스케어 컨퍼런스에서 발표할 예정입니다. 두 행사는 모두 뉴욕에서 열리며, 편안한 대화와 일대일 미팅이 포함됩니다.
투자자들은 회사 웹사이트 investors.mbxbio.com/news-events/events를 통해 두 발표의 생중계 웹캐스트를 시청할 수 있습니다. 각 행사가 끝난 약 두 시간 후에 다시보기 녹화가 제공되며, 90일 동안 이용 가능합니다.
MBX Biosciences (Nasdaq : MBX), une société biopharmaceutique en phase clinique spécialisée dans les thérapies peptidiques de précision pour les troubles endocriniens et métaboliques, a annoncé sa participation à deux grandes conférences pour investisseurs en mai 2025.
Le président-directeur général de la société, Kent Hawryluk, interviendra lors de la Citizens Life Sciences Conference le 7 mai 2025 (15h00-15h25 ET) et lors de la RBC 2025 Global Healthcare Conference le 21 mai 2025 (15h35-16h00 ET). Les deux événements se tiendront à New York et comprendront des discussions informelles ainsi que des rencontres individuelles.
Les investisseurs pourront accéder aux webinaires en direct des deux présentations via le site internet de la société à l'adresse investors.mbxbio.com/news-events/events. Les enregistrements seront disponibles environ deux heures après chaque événement et resteront accessibles pendant 90 jours.
MBX Biosciences (Nasdaq: MBX), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf präzise Peptidtherapien für endokrine und metabolische Erkrankungen spezialisiert hat, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im Mai 2025 angekündigt.
Der Präsident und CEO des Unternehmens, Kent Hawryluk, wird auf der Citizens Life Sciences Conference am 7. Mai 2025 (15:00-15:25 Uhr ET) und auf der RBC 2025 Global Healthcare Conference am 21. Mai 2025 (15:35-16:00 Uhr ET) präsentieren. Beide Veranstaltungen finden in New York statt und umfassen informelle Gespräche sowie Einzelgespräche.
Investoren können beide Präsentationen live über die Website des Unternehmens unter investors.mbxbio.com/news-events/events verfolgen. Aufzeichnungen werden etwa zwei Stunden nach jeder Veranstaltung verfügbar sein und für 90 Tage abrufbar bleiben.
- None.
- None.
CARMEL, Ind., April 22, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at and participate in the Citizens Life Sciences Conference on May 7 and the RBC 2025 Global Healthcare Conference on May 21.
The Citizens Life Sciences Conference
Date: Wednesday, May 7, 2025
Format: Fireside chat and 1x1 meetings
Time: 3:00 p.m. – 3:25 p.m. ET
Location: New York, NY
The RBC 2025 Global Healthcare Conference
Date: Wednesday, May 21, 2025
Format: Fireside chat and 1x1 meetings
Time: 3:35 p.m. – 4:00 p.m. ET
Location: New York, NY
The live webcast for each presentation can be accessed in the investors section of the MBX Biosciences website at https://investors.mbxbio.com/news-events/events. Access to the webcast replays will be available approximately two hours after the completion of the events and will be archived on the Company’s website for approximately 90 days.
About MBX Biosciences
MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism (HP) in Phase 2 development; MBX 1416 for the treatment of post-bariatric hypoglycemia (PBH) in Phase 1 development; and an obesity portfolio that includes MBX 4291, with an IND submission anticipated in Q2 2025, as well as multiple discovery and pre-clinical obesity candidates. The Company is based in Carmel, Indiana. To learn more, please visit the Company website at https://mbxbio.com/ and follow it on LinkedIn.
Media Contact:
Katie Beach Oltsik
Inizio Evoke Comms
katie.beach@inizioevoke.com
(937) 232-4889
Investor Contact:
Jim DeNike
MBX Biosciences
jdenike@mbxbio.com
FAQ
When and where will MBX Biosciences present at the Citizens Life Sciences Conference in May 2025?
How can investors access MBX Biosciences' May 2025 conference presentations?
What type of therapies is MBX Biosciences developing?
What is the schedule for MBX Biosciences' presentation at the RBC 2025 Global Healthcare Conference?
